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Case Report

Innovative Use of Biotrace Tempo Pacemaker Lead
Following Cardiac Surgery
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ABSTRACT
The Tempo® Temporary Pacing Lead is a temporary, transvenous, active fixation pacemaker lead used exclusively in structural heart and
electrophysiology procedures since regulatory approval in 2016. We utilized the Tempo lead for four patients undergoing redo‑robotic cardiac
surgery in which surgical epicardial leads could not be placed. No failure‑to‑pace events were encountered and patients were able to participate
in various levels of physical activity without limitation.
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INTRODUCTION

The Tempo Temporary Pacing Lead has been used in
structural heart and electrophysiology procedures for
temporary pacemaking since regulatory approval in
2016.[1] The lead is a temporary, transvenous, active‑fixation
pacemaker. The Tempo lead may have distinct advantages
compared to epicardial leads traditionally used in the
perioperative period for cardiac surgery, and this report is
the first documented use of this device following cardiac
surgery. Written HIPAA authorization was obtained for
publication of this report.
CASE REPORT

A 58‑year‑old man with a history of mitral and aortic
valve replacement presented for redo‑robotic mitral valve
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replacement for severe prosthetic mitral stenosis. Due to
prior sternotomy and robotic approach, surgical exposure
for placement of a traditional right ventricular epicardial
pacemaker was limited; therefore, the anesthesiology team
planned to place a preoperative Tempo® Temporary
Pacing Lead (BioTrace Medical, Menlo Park CA, USA) for
postoperative pacing. The Tempo lead is an active fixation,
bipolar pacing electrode and is FDA approved for use as a
temporary transvenous pacemaker.
General anesthesia was induced with standard monitors
and an arterial line. Following endotracheal intubation
with a 37L double lumen endotracheal tube, right internal
jugular 11Fr and 9Fr sheaths were placed under continuous
ultrasound guidance. A ProPledge (Edwards Life Sciences,
Irvine CA, USA) percutaneous coronary sinus catheter
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was positioned in the coronary sinus via the 11Fr sheath
using fluoroscopy and transesophageal echocardiography;
pulmonary EndoVent (Edwards Life Sciences, Irvine
CA, USA) was positioned in the main pulmonary artery
via the 9 Fr sheath. Left internal jugular vein was accessed
with a 7Fr sheath with ultrasound guidance. The Tempo
lead was advanced via the 7Fr sheath into the apex of
the right ventricle with fluoroscopic guidance. Following
fluoroscopic confirmation of position, the balloon at
the tip of the lead was inflated, forcing apposition of
the tip of the lead to the apical ventricular septum.
Stabilizer loops were then released to anchor the lead to
the endocardium [Figure 1] and the balloon deflated. The
Tempo lead was tested and captured successfully at 0.8 mA.
Cardiopulmonary bypass (CPB) was initiated with
percutaneous femoral arterial and bicaval cannulation.
Cross‑clamp of the ascending aorta was applied using
the IntraClude (Edwards Life Sciences, Irvine CA, USA)
endovascular aortic cross‑clamp. Delnido cardioplegia
was delivered in antegrade and retrograde fashion using
both the Intraclude and Propledge devices. Robotic
mitral valve replacement with #31 bioprosthetic valve was
performed without complication via three 8 mm ports
in the right thorax. The patient was weaned from CPB
in sinus rhythm; total CPB time and cross‑clamp time
were 179 and 91 minutes, respectively. The patient was
transitioned to the ICU in sinus rhythm on epinephrine
0.06 mcg/kg/min, phenylephrine 1.5 mcg/kg/min, and
vasopressin 0.04 units/min. Tempo pacemaker was set to
VVI at 50 beats per minute (bpm) for backup pacemaking
in the event of bradycardia or complete heart block. The
patient was extubated on postoperative day (POD) 0.

Early on POD #1 he was out of bed to chair. The patient
required intermittent pacing using the Tempo lead at
80 bpm for hypotension. The patient was able to walk with
assistance with indwelling Tempo lead. On POD #2 he was
hemodynamically stable, in sinus rhythm, and the Tempo
lead was removed at the bedside. The stabilizer loops were
retracted and the lead removed with gentle traction through
the vascular sheath [Figure 2].
Since this initial clinical experience, we have used the
Tempo lead in three additional patients [Table 1]. With
the active‑fixation lead in place, patients were able to
participate in varied levels of physical activity without
limitation. No complications related to perforation or
tamponade have occurred in our clinical experience.
DISCUSSION

Following cardiac surgery, epicardial pacemakers are
routinely placed to prevent hemodynamically significant
bradycardia, complete heart block, or other rhythm
disturbances. However, clinical scenarios, such as the
redo‑robotic surgical approach, may prohibit placement
of traditional epicardial electrodes. In this setting,
an alternative pacemaker option must be considered.
A conventional transvenous pacemaker or a Paceport
pulmonary artery catheter may act as a suitable alternative
for postoperative pacemaking if epicardial access is limited;
however, continuous pacemaker capture may be unreliable
in large or small hearts. Electrodes may be displaced with
patient movement; therefore, patient activity must be
restricted with transvenous pacemaking techniques.[2,3] The
Table 1: Patient Details
Case Surgery

Access Removed Out of bed Pacemaker
with Tempo
related
complication

1

Left IJ

POD 2

Yes

No

Left IJ

POD 2

Yes

No

Right IJ POD 1

Yes

No

Left IJ

Yes

No

2
3
4

Redo‑Robotic
MV Repair
Redo‑Robotic
MV Replacement
Redo‑Robotic
MV Repair
Redo‑Robotic
MV Repair

POD 3

IJ=Internal jugular vein, POD=Post‑operative day, MV=Mitral valve

Figure 1: Air‑filled balloon ensures Tempo lead tip is apposed to
septal wall in the right ventricular apex. Stabilizer loops are deployed
to provide active lead fixation to the endocardium
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a

b

Figure 2: (a) Stabilizer loops deployed with trigger in locked position. (b)
Stabilizer loops retracted with trigger in unlocked position
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Tempo lead has an innovative active‑fixation system which
allows for reliable pacemaker capture, increased patient
activity, and participation in early physical therapy. In our
experience, the use of the Tempo lead has enabled early
mobilization and physical therapy in a patient population
that would have otherwise had activity restriction.
Cardiac tamponade is a life‑threatening event occurring in
1% of patients in whom epicardial leads are removed with
traction.[4] Although they may cause direct damage to heart
tissue, epicardial leads are often removed in the presence
of limited hemodynamic monitoring. As an alternative to
removal, epicardial leads may be left in situ and cut at the
skin. Leads remaining in the chest cavity are at risk for
migration and infection. Retained epicardial leads have
been localized to the aorta, pulmonary artery, esophagus,
lung, colon, and soft tissue of the chest, head, and neck.[5‑9]
The Tempo lead is removed through the intravascular
sheath when temporary pacing is no longer indicated.
The stabilizer loops are retracted and the lead removed
with gentle traction through the intravascular sheath. To
date, no reports of perforation or myocardial injury have
occurred during removal of the Tempo lead.
The Tempo lead has a soft, flexible tip designed to mitigate
perforation events during lead placement. If a catastrophic
event were to occur, lead placement is a relatively “safer”
time for perforation compared to lead removal. During
lead placement, patients are in the operating room with
invasive monitoring including, arterial line, pulmonary
artery catheter, and transesophageal echocardiography.
In addition, a cardiac surgeon, immediately capable of
relieving tamponade, is either present or immediately
available. Invasive monitoring and personnel in the
operative suite allow for immediate diagnosis and definitive
treatment of cardiac tamponade in the rare occurrence of
a perforation event.
Since regulatory approval, the Tempo lead has been used
safely and effectively in structural heart procedures with
zero reported occurrences of cardiac perforation, effusion,
or tamponade.[10] We present the first documented use
of the Tempo lead following cardiac surgery. Potential
advantages of the Tempo lead, as compared to traditional
epicardial leads, are: (1) Transvenous approach allows
for reliable pacemaking when epicardial lead placement
is challenging. (2) Active‑fixation provides stability of
the temporary pacemaker and allows for increased
patient activity and participation in early physical therapy.
(3) Reports of myocardial injury and tamponade with the
Tempo lead are exceedingly rare. While perforation and
tamponade are also rare with traditional epicardial leads,
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when they do occur, it is a life‑threatening complication
in a relatively unmonitored setting. Design of the Tempo
lead mitigates the risk of myocardial perforation during
lead placement (due to the soft, flexible tip) and at lead
removal (stabilizer loops retract into the device and
the lead is removed with gentle traction through the
intravascular sheath). Overall, the Tempo lead platform has
intriguing potential for future use to facilitate postoperative
pacemaking in cardiac surgery. However, prior to
widespread adoption of the Tempo platform, reliability
of pace capture thresholds must be widely verified in a
post‑cardiotomy population.
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